Conjugates of γ 3-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Makhaeva, Galina F ^a   Lushchekina, Sofya V ^a,b   Boltneva, Natalia P ^a   Sokolov, Vladimir B ^a   Grigoriev, Vladimir V ^a   Serebryakova, Olga G ^a   Vikhareva, Ekaterina A ^a   Aksinenko, Alexey Yu ^a   Barreto, George E ^c,d   Aliev, Gjumrakch ^e,f   Bachurin, Sergey O ^a  

^a INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^b EMANUEL INSTITUTE OF BIOCHEMICAL PHYSICS   (Russian Federation)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^d UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^e GALLY International Biomedical Research Consulting LLC   (United States)

^f University of Atlanta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOLINE DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DRUG COMBINATION; GAMMA-CARBOLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENOTHIAZINE; PHENOTHIAZINE DERIVATIVE; PROTEIN BINDING;

ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL MODEL; CHEMISTRY; DOSE RESPONSE; DRUG COMBINATION; DRUG DESIGN; ENZYME ACTIVATION; HUMAN; METABOLISM; MOLECULAR DOCKING; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANIMALS; BINDING SITES; BUTYRYLCHOLINESTERASE; CARBOLINES; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG DESIGN; ENZYME ACTIVATION; HUMANS; MODELS, CHEMICAL; MOLECULAR DOCKING SIMULATION; PHENOTHIAZINES; PROTEIN BINDING; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 84939447595     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13164     Document Type: Article

References (63)

1. Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J. & Drago, F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British journal of clinical pharmacology 73, 504-517, doi: 10.1111/j.1365-2125.2011.04134.x (2012).
2. Youdim, M. B. Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents. Experimental neurobiology 19, 1-14, doi: 10.5607/en.2010.19.1.1 (2010).
3. Carreiras, M. C., Mendes, E., Perry, M. J., Francisco, A. P. & Marco-Contelles, J. The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Current topics in medicinal chemistry 13, 1745-1770 (2013).
4. Eisen, A. Amyotrophic lateral sclerosis: A 40-year personal perspective. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia 16, 505-512, doi: 10.1016/j.jocn.2008.07.072 (2009).
5. Bachurin, S. O. [Medicinal and chemical approaches to focused search of agents for treatment and therapy of Alzheimer disease]. Voprosy meditsinskoi khimii 47, 155-197 (2001).
6. Calza, L. et al. From the multifactorial nature of Alzheimer's disease to multitarget therapy: the contribution of the translational approach. Current topics in medicinal chemistry 13, 1843-1852 (2013).
7. Geldenhuys, W. J. & Van der Schyf, C. J. Rationally designed multi-targeted agents against neurodegenerative diseases. Current medicinal chemistry 20, 1662-1672 (2013).
8. Guzior, N., Wieckowska, A., Panek, D. & Malawska, B. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. Current medicinal chemistry 22, 373-404 (2015).
9. Blasco, H., Mavel, S., Corcia, P. & Gordon, P. H. The glutamate hypothesis in ALS: pathophysiology and drug development. Current medicinal chemistry 21, 3551-3575 (2014).
10. Cacabelos, R., Takeda, M. & Winblad, B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. International journal of geriatric psychiatry 14, 3-47 (1999).
11. Mufson, E. J., Counts, S. E., Perez, S. E. & Ginsberg, S. D. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert review of neurotherapeutics 8, 1703-1718, doi: 10.1586/14737175.8.11.1703 (2008).
12. Canas, P. M., Simoes, A. P., Rodrigues, R. J. & Cunha, R. A. Predominant loss of glutamatergic terminal markers in a betaamyloid peptide model of Alzheimer's disease. Neuropharmacology 76 Pt A, 51-56, doi: 10.1016/j.neuropharm.2013.08.026 (2014).
13. Parsons, C. G., Danysz, W., Dekundy, A. & Pulte, I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotoxicity research 24, 358-369, doi: 10.1007/s12640-013-9398-z (2013).
14. Martinez, A. & Castro, A. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert opinion on investigational drugs 15, 1-12, doi: 10.1517/13543784.15.1.1 (2006).
15. Rodda, J. & Carter, J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. Bmj 344, e2986, doi: 10.1136/bmj.e2986 (2012).
16. Wilkinson, D. G., Francis, P. T., Schwam, E. & Payne-Parrish, J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs & aging 21, 453-478 (2004).
17. Francis, P. T., Parsons, C. G. & Jones, R. W. Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. Expert review of neurotherapeutics 12, 1351-1365, doi: 10.1586/ern.12.124 (2012).
18. Grossberg, G. T., Edwards, K. R. & Zhao, Q. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. Journal of clinical pharmacology 46, 17S-26S, doi: 10.1177/0091270006288735 (2006).
19. Rosini, M., Simoni, E., Minarini, A. & Melchiorre, C. Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochemical research 39, 1914-1923, doi: 10.1007/s11064-014-1250-1 (2014).
20. Oz, M., Lorke, D. E. & Petroianu, G. A. Methylene blue and Alzheimer's disease. Biochemical pharmacology 78, 927-932, doi: 10.1016/j.bcp.2009.04.034 (2009).
21. Atamna, H. & Kumar, R. Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. Journal of Alzheimer's disease: JAD 20 Suppl 2, S439-452, doi: 10.3233/JAD-2010-100414 (2010).
22. Bharadwaj, P. R. et al. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Translational psychiatry 3, e332, doi: 10.1038/tp.2013.97 (2013).
23. Cano-Cuenca, N., Solis-Garcia del Pozo, J. E. & Jordan, J. Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. Journal of Alzheimer's disease: JAD 38, 155-164, doi: 10.3233/JAD-130872 (2014).
24. Steele, J. W. & Gandy, S. Latrepirdine (Dimebon(R), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy 9, 617-618, doi: 10.4161/auto.23487 (2013).
25. Yamashita, M. et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS letters 583, 2419-2424, doi: 10.1016/j.febslet.2009.06.042 (2009).
26. Bachurin, S. O. et al. Derivatives of 1, 2, 3, 4-tetrahydropyrido [4, 3-b]indole containing phenothiazines as inhibitors of cholinesterases and blockers of serotonin 5-HT6 receptors, methods for their synthesis and pharmacological agent on their base. Russia patent #2530881(2014).
27. Bachurin, S. O. et al. Derivatives of phenothiazine containing 1, 2, 3, 4-tetrahydropyrido [4, 3-b]indoles as agents for reducing uncontrolled protein aggregation in nervous system, methods for their synthesis, pharmacological agent on this base and method for reducing uncontrolled protein aggregation in nervous system. Russia patent #2529899(2014).
28. Darvesh, S. et al. Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. Journal of medicinal chemistry 51, 4200-4212, doi: 10.1021/jm8002075 (2008).
29. Darvesh, S. et al. Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorganic & medicinal chemistry 18, 2232-2244, doi: 10.1016/j.bmc.2010.01.066 (2010).
30. Sezgin, Z., Biberoglu, K., Chupakhin, V., Makhaeva, G. F. & Tacal, O. Determination of binding points of methylene blue and cationic phenoxazine dyes on human butyrylcholinesterase. Archives of biochemistry and biophysics 532, 32-38, doi: 10.1016/j. abb.2013.01.003 (2013).
31. Simeon-Rudolf, V., Sinko, G., Stuglin, A. & Reiner, E. Inhibition of human blood acetylcholinesterase and butyrylcholinesterase by ethopropazine. Croat Chem Acta 74, 173-182 (2001).
32. Grigoriev, V. V., Dranyi, O. A. & Bachurin, S. O. Comparative study of action mechanisms of dimebon and memantine on AMPA-and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bulletin of experimental biology and medicine 136, 474-477 (2003).
33. Imai, T. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug metabolism and pharmacokinetics 21, 173-185 (2006).
34. Laizure, S. C., Herring, V., Hu, Z., Witbrodt, K. & Parker, R. B. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 33, 210-222, doi: 10.1002/phar.1194 (2013).
35. Tsurkan, L. G., Hatfield, M. J., Edwards, C. C., Hyatt, J. L. & Potter, P. M. Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chemico-biological interactions 203, 226-230, doi: 10.1016/j.cbi.2012.10.018 (2013).
36. Heymann, E. & Krisch, K. [Phosphoric acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxylesterases]. Hoppe-Seyler's Zeitschrift fur physiologische Chemie 348, 609-619 (1967).
37. Darvesh, S. et al. Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives. Bioorganic & medicinal chemistry 13, 211-222, doi: 10.1016/j.bmc.2004.09.059 (2005).
38. Makhaeva, G. F. et al. Combined QSAR studies of inhibitor properties of O-phosphorylated oximes toward serine esterases involved in neurotoxicity, drug metabolism and Alzheimer's disease. SAR and QSAR in environmental research 23, 627-647, doi: 10.1080/1062936X.2012.679690 (2012).
39. Makhaeva, G. F. et al. Organophosphorus compound esterase profiles as predictors of therapeutic and toxic effects. Chemicobiological interactions 203, 231-237, doi: 10.1016/j.cbi.2012.10.012 (2013).
40. Darvesh, S. et al. Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorganic & medicinal chemistry 15, 6367-6378, doi: 10.1016/j.bmc.2007.06.060 (2007).
41. Greig, N. H. et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Current medical research and opinion 17, 159-165, doi: 10.1185/0300799039117057 (2001).
42. Lane, R. M., Potkin, S. G. & Enz, A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 9, 101-124, doi: 10.1017/S1461145705005833 (2006).
43. Wang, L. et al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. European journal of medicinal chemistry 80, 543-561, doi: 10.1016/j.ejmech.2014.04.078 (2014).
44. Kamal, M. A. et al. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochemical research 33, 745-753, doi: 10.1007/s11064-007-9490-y (2008).
45. Greig, N. H. et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proceedings of the National Academy of Sciences of the United States of America 102, 17213-17218, doi: 10.1073/pnas.0508575102 (2005).
46. Nordberg, A. et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Current Alzheimer research 6, 4-14 (2009).
47. Samadi, A. et al. Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. European journal of medicinal chemistry 67, 64-74, doi: 10.1016/j.ejmech.2013.06.021 (2013).
48. Weinstock, M. & Groner, E. Rational design of a drug for Alzheimer's disease with cholinesterase inhibitory and neuroprotective activity. Chemico-biological interactions 175, 216-221, doi: 10.1016/j.cbi.2008.03.014 (2008).
49. Macdonald, I. R., Rockwood, K., Martin, E. & Darvesh, S. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer? Journal of Alzheimer's disease: JAD 42, 379-384, doi: 10.3233/JAD-140219 (2014).
50. Ellman, G. L., Courtney, K. D., Andres, V., Jr. & Feather-Stone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical pharmacology 7, 88-95 (1961).
51. Sterri, S. H., Johnsen, B. A. & Fonnum, F. A radiochemical assay method for carboxylesterase, and comparison of enzyme activity towards the substrates methyl [1-14C] butyrate and 4-nitrophenyl butyrate. Biochemical pharmacology 34, 2779-2785 (1985).
52. Zhou, L. M. et al. (2S, 4R)-4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors. The Journal of pharmacology and experimental therapeutics 280, 422-427 (1997).
53. Coughenour, L. L. & Barr, B. M. Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits. The Journal of pharmacology and experimental therapeutics 296, 150-159 (2001).
54. Dana, C., Benavides, J., Schoemaker, H. & Scatton, B. Pharmacological characterisation and autoradiographic distribution of polyamine-sensitive [3H]ifenprodil binding sites in the rat brain. Neuroscience letters 125, 45-48 (1991).
55. Nowak, G., Trullas, R., Layer, R. T., Skolnick, P. & Paul, I. A. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. The Journal of pharmacology and experimental therapeutics 265, 1380-1386 (1993).
56. Schmidt, M. W. et al. General atomic and molecular electronic structure system. Journal of Computational Chemistry 14, 1347-1363 (2004).
57. Mulliken, R. S. Electronic population analysis on LCAO-MO molecular wave functions. Journal of Chemical Physics 23, 1841-1846 (1955).
58. Berman, H. M. et al. The Protein Data Bank. Nucleic acids research 28, 235-242 (2000).
59. Nicolet, Y., Lockridge, O., Masson, P., Fontecilla-Camps, J. C. & Nachon, F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. The Journal of biological chemistry 278, 41141-41147, doi: 10.1074/jbc.M210241200 (2003).
60. Masson, P., Lushchekina, S., Schopfer, L. M. & Lockridge, O. Effects of viscosity and osmotic stress on the reaction of human butyrylcholinesterase with cresyl saligenin phosphate, a toxicant related to aerotoxic syndrome: kinetic and molecular dynamics studies. The Biochemical journal 454, 387-399, doi: 10.1042/BJ20130389 (2013).
61. Lushchekina, S. V., Polomskikh, V. S., Varfolomeev, S. D. & Masson, P. Molecular modeling of butyrylcholinesterase inhibition by cresyl saligenin phosphate. Russian Chemical Bulletin 62, 2527-2537 doi: 10.1007/s11172-013-0366-9 (2013).
62. Morris, G. M. et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry 19, 1639-1662 (1999).
63. Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30, 2785-2791, doi: 10.1002/jcc.21256 (2009).